Recently Featured

Adragos Pharma Finalizes the Acquisition of Commercial-Scale, Sterile Fill-Finish Manufacturing Site From Sanofi

April 7, 2026
Adragos Pharma recently announced the completion of its acquisition of a commercial-scale sterile fill-finish facility located in Maisons-Alfort, France, from Sanofi. This site is recognized as one of Europe’s largest manufacturing facilities for sterile injectables, featuring industrial-scale capacity for pre-filled syringes, liquids, and lyophilized vials. The Maisons-Alfort facility is routinely audited by international health authorities,…

Lilly Secures FDA Approval for Foundayo, Setting New Standard in GLP-1 Therapy

April 6, 2026
The FDA has approved Lilly’s GLP-1 receptor agonist pill, Foundayo, marking it as the first new molecular entity to be cleared under the regulator’s controversial Commissioner’s National Priority Voucher program. This approval is a significant milestone for Lilly, positioning the company to compete directly with Novo Nordisk’s established GLP-1 therapies, which have dominated the market.…

FDA’s Leadership Instability Leaves Drugmakers in Uncertainty

April 6, 2026
Constant leadership changes and erratic decision-making at the FDA have left the biopharmaceutical industry feeling that its chief regulator is more unpredictable than ever. Over the past year, the agency has experienced significant turnover in key positions, which has contributed to a lack of clarity in regulatory guidance and approval processes. This instability comes at…

Eli Lilly Outlays $7.8bn to Acquire Sleep Drug Biotech Centessa

April 5, 2026
Eli Lilly has announced a significant acquisition, committing $7.8 billion to purchase Centessa Pharmaceuticals, a biotech firm focused on developing innovative treatments for sleep disorders. This strategic move underscores Lilly’s intent to enhance its portfolio in the competitive sleep medicine market, particularly as demand for effective therapies continues to rise amid increasing awareness of sleep-related…

Ongoing Cases